Are Theravance And Mylan's US COPD Chances Bigger Than First Thought?
With Theravance Biopharma's promising once-daily nebulized LAMA bronchodilator, partnered with Mylan, set for FDA filing later this year, analysts say the product might have a bigger market than initially presumed, and are now looking beyond to the firm's other pipeline activities.
You may also be interested in...
Theravance Uses Organ-Selective R&D To Advance GI, Pulmonary Candidates
Company develops selective JAK inhibitors for IBD and pulmonary disease that are intended to clear the body before systemic side effects can occur. It also has a drug candidate for NOH that analysts think is underappreciated.
Mylan/Theravance’s Yupelri Will Launch Late This Year To Address COPD Niche
Yupelri was approved by the US FDA as the first nebulized long-acting muscarinic antagonist for once-daily treatment of chronic obstructive pulmonary disease.
Mylan CEO Heather Bresch On How Mylan Is Different Than Teva
CEO Heather Bresch talked to Scrip about how she will navigate the company through what has become a rough period for the US generic drug market and validation on complex generics and biosimilars.